Phase III CANVAS Trial Results Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes

October 2, 2012
Janssen Research & Development announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for Type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.